TRPV1 and Parkinson disease: Benefits of the CBR/TRPV1 axis for neurodegenerative diseases has been suggested by some studies due to CBRs and TRPV1 inhibition of glial activation and expression of proinflammatory cytokines in a mouse model of Parkinson’s disease (Wi et al., 2020).